18F-FDG PET/CT Mean SUV and Metabolic Tumor Volume for Mean Survival Time in Non-Small Cell Lung Cancer
18F-FDG PET/CT Mean SUV and Metabolic Tumor Volume for Mean Survival Time in Non-Small Cell Lung Cancer
复制标题
DOI：
10.1097/rlu.0000000000000740
复制
发表时间：
2015-06-01
影响因子：
10.6
通讯作者：
Bekci, Taha Tahir
中科院分区：
文献类型：
--
作者：
Kurtipek, Ercan;Cayci, Mustafa;Bekci, Taha Tahir
目的：本研究旨在确定标准化摄取值与生存时间的关系，（SUVmax和SUVmean）和代谢肿瘤体积（MTV）在非小细胞肺癌（NSCLC）患者中的应用，并研究这些患者的人口统计学、临床和放射学数据对生存率的影响。我们对2010年5月至2013年3月期间来我院就诊的79例NSCLC患者的记录进行了回顾性分析，接受了最终诊断，并接受F-18-FDG PET/CT进行分期。记录并统计分析对预后有影响的临床、放射学和F-18-FDG PET/CT参数，例如通过初始诊断期间F-18-FDG PET/CT扫描中的感兴趣体积区域计算的原发性肿瘤的SUVmax、肿瘤的平均SUV和以SUVmax大于2.5的阈值获得的MTV。根据患者的临床、影像学和PET/CT表现进行统计学分析，将患者分为2组：幸存者和非幸存者。结果：70例患者（88.6%）为男性，9例（11.4%）为女性。非存活组（n = 40）的平均年龄为63.65 ± 11.51岁，而存活组（n = 39）的平均年龄为62.74 ± 10.60岁（表1）。非存活者组诊断后的平均生存时间为7.9 ± 6.52个月，而存活者组为14.09 ± 7.41个月。60岁或以下患者的平均生存时间为12.9 +/- 7.9个月，而60岁或以上患者的平均生存时间为9.9 +/- 7.2年。根据考克斯回归分析，较高的MTV [相对危险度（RR），1.006; P = 0.03]和平均SUVmax（mSUV）（RR，1.302; P = 0.03）对平均生存时间的缩短有显著影响。然而，SUVmax测量值未达到统计学显著性（RR，0.970; P = 0.39）。此外，肿瘤大小的增加（
Objective: The study was designed to determine the relationship between survival time of standardized uptake value (SUVmax and SUVmean) andmetabolic tumor volume (MTV) in patients with non-small cell lung cancer (NSCLC), and examine the impact of demographic, clinical, and radiological data of these patients on survival.Materials and Methods: We performed a retrospective analysis of the records of 79 patients with NSCLC who presented to our hospital between May 2010 and March 2013, received a final diagnosis, and underwent F-18-FDG PET/CT for staging. Clinical, radiological, and F-18-FDG PET/CT parameters with an impact on prognosis such as the SUVmax of the primary tumor as calculated by the volumetric region of interest in the F-18-FDG PET/CT scans during initial diagnosis, mean SUV of the tumor, and MTV obtained with a threshold of SUVmax greater than 2.5 were recorded and statistically analyzed. A statistical analysis was carried out based on the clinical, radiological, and PET/CT findings of the patients who were divided into 2 groups: survivors and nonsurvivors.Results: Seventy patients (88.6%) were men, and 9 (11.4%) were women. The mean age was 63.65 +/- 11.51 years in the nonsurvivor group (n = 40) versus 62.74 +/- 10.60 years in the survivor group (n = 39) (Table 1). The mean survival time from diagnosis was 7.9 +/- 6.52 months in the nonsurvivor group versus 14.09 +/- 7.41 months in the survivor group. The mean survival time was 12.9 +/- 7.9 months for those aged 60 or younger, whereas it was 9.9 +/- 7.2 years for those aged 60 or older. According to the Cox regression analysis, higher MTV [relative risk (RR), 1.006; P = 0.03] and mean SUVmax (mSUV) (RR, 1.302; P = 0.03) had a significant impact on shortening of the mean survival time. However, no statistical significance was reached for SUVmax measurements (RR, 0.970; P = 0.39). Furthermore, there was a significant relationship between increased tumor size (